NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

just go back and see what happened to Dendreon when they completed their first phase 3.

Won't happen here. NWBO is making sure that all of the patients are well over 40 months past their last surgery. That will allow the derived 5 year survival figures to be quite reliable. Most likely around 20% of the trial patients will be alive 5 years past their surgery and I expect SOC to have a 5 year survival which is SS less than that of trial. These results will probably be unassailable and with NICE also considering the treatment, the FDA will have a difficult time turning down a treatment that NICE is likely to incorporate. I think LP is aware of all the pitfalls and the unusual length of this trial is designed to minimize the risks of failure.

I believe that the thick long tail will overshadow the mPFS and mOS results and will carry this trial to success.